Precision Optics Corporation, Inc. — Form 10-Q Summary
Reporting period: The filing covers the third quarter and nine months of fiscal 2015, ended March 31, 2015. Although the request metadata says “2014 Q3,” the filing itself reports fiscal 2015. Results are unaudited and consolidated.
Business context
The company develops and manufactures optical instruments, with most business focused on medical devices, including endoscopes, micro-imaging systems and surgical visualization products. Approximately 10% of its business is military and industrial products. About 55% of nine-month sales came from five customers, creating meaningful customer concentration.
Financial performance and liquidity
| Metric | Quarter ended March 31, 2015 | Quarter ended March 31, 2014 | Nine months ended March 31, 2015 | Nine months ended March 31, 2014 |
|---|---|---|---|---|
| Revenue | $1,141,892 | $833,451 | $2,949,154 | $2,748,594 |
| Gross profit (margin) | $312,929 (27.4%) | $189,232 (22.7%) | $587,579 (19.9%) | $654,882 (23.8%) |
| Operating loss | $237,106 | $380,434 | $854,768 | $843,608 |
| Net loss | $197,884 | $380,434 | $815,546 | $843,608 |
| Loss per share, basic and diluted | $0.03 | $0.09 | $0.13 | $0.19 |
At March 31, 2015, cash was $283,275, accounts receivable $542,473, inventory $1,248,742, current assets $2,145,316 and current liabilities $1,309,171. The balance sheet reports no debt balance; the company stated it was not in default on indebtedness. Stockholders’ equity was $914,360. Cash increased $80,895 over the nine months, supported by $858,779 of net financing cash proceeds, while operating activities used $724,840 and investing activities used $53,044. The company reported $64,639 of operating cash use during the quarter.
Changes versus prior comparable periods
- Quarterly revenue rose 37.0%, driven mainly by higher sales of surgical visualization and newer small-fiber-scope and micro-imaging products, plus engineering services.
- Nine-month revenue rose 7.3%, but gross profit fell $67,303 and gross margin declined 3.9 percentage points, attributed to product mix and startup costs for new products.
- Quarterly gross margin improved, which management attributed to higher volume and a more favorable product mix. Quarterly operating and net losses narrowed, helped by higher gross profit and lower selling, general and administrative expenses.
- Nine-month net loss narrowed modestly despite the lower gross profit; operating loss increased slightly. Other income included a noncash $39,222 gain from settling service liabilities with stock.
Outlook, risks and unusual items
- No quantified revenue, earnings or cash-flow guidance is provided. Management believes newer optical technologies and products could support growth and eventual breakeven, but the company continues to incur losses.
- Management says additional financing may be needed until breakeven, potentially through debt, equity or a strategic alliance. Financing may not be available on acceptable terms; further equity financing could dilute shareholders.
- The July 2014 private placement sold 1,717,152 shares at $0.60 each for $1,030,291 gross proceeds. The share count rose from 4,455,134 at June 30, 2014 to 6,344,806 at March 31, 2015. The placement also triggered anti-dilution adjustments to certain existing warrants.
- Cash and working capital require monitoring: inventory increased about $260,000 from June 30, and current liabilities exceeded cash substantially. Approximately $195,000 owed to a component supplier has extended installment terms; open purchase orders totaled about $330,000, including about $184,000 tied to a customer whose delivery schedule was being renegotiated.
- Management concluded disclosure controls were ineffective as of March 31, 2015, citing longstanding material weaknesses involving segregation of duties and inventory valuation. It described review and inventory-control measures but could not guarantee remediation.
- Competition includes larger, better-resourced companies; sales are concentrated among a small number of customers. The filing reports no material changes to previously disclosed risk factors and no known litigation expected to have a material impact.
Most important facts for investors to verify
- Whether new-product sales and production volumes can improve nine-month gross margins and lead to sustained profitability.
- Cash needs, liquidity runway and availability or terms of additional financing.
- Customer concentration, the status of renegotiated delivery timing, and collection of receivables.
- Inventory valuation and the status of remediation of the disclosed material weaknesses in internal controls.
- The potential dilution from issued shares, outstanding warrants and the April 2015 increase of 1.5 million shares available under the equity incentive plan.